Cargando…

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma

INTRODUCTION: Somatostatin analogues exert antitumour activity via direct and indirect mechanisms. The present study was designed to assess the safety and efficacy of pasireotide in patients with BRAF-wild type (WT) and NRAS-WT metastatic melanoma. PATIENTS AND METHODS: Patients with unresectable an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dummer, Reinhard, Michielin, Olivier, Nägeli, Mirjam Chantal, M. Goldinger, Simone, Campigotto, Federico, Kriemler-Krahn, Ulrike, Schmid, Herbert, Pedroncelli, Alberto, Micaletto, Sara, Schadendorf, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069912/ https://www.ncbi.nlm.nih.gov/pubmed/30094073 http://dx.doi.org/10.1136/esmoopen-2018-000388

Ejemplares similares

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study
por: Momenzadeh, Hooria, et al.
Publicado: (2018)

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas
por: Posch, Christian, et al.
Publicado: (2018)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
por: Sorah, Jonathan D, et al.
Publicado: (2022)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition
por: Yeom, Hojin, et al.
Publicado: (2021)

Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis
por: Lv, Xiao, et al.
Publicado: (2018)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer
por: Carter, Rebecca, et al.
Publicado: (2019)

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study
por: Lastraioli, Elena, et al.
Publicado: (2022)

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study
por: Granieri, Stefano, et al.
Publicado: (2022)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial
por: Li, Danyang, et al.
Publicado: (2021)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
por: Feun, Lynn G, et al.
Publicado: (2018)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
por: Zhang, Wen, et al.
Publicado: (2022)

The Report of KRAS Mutation and NRAS Wild Type in a Patient with Thyroid Metastasis from Colon Cancer: a Rare Case Report
por: Payandeh, Mehrdad, et al.
Publicado: (2016)

Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
por: Tóth, Béla, et al.
Publicado: (2020)

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
por: Urbonas, V, et al.
Publicado: (2019)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
por: Adams, Richard, et al.
Publicado: (2017)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
por: Segelov, Eva, et al.
Publicado: (2016)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

Vemurafenib-resistant BRAF selects alternative branch points different from its wild-type BRAF in intron 8 for RNA splicing
por: Ajiro, Masahiko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9n5jlgbg0gaoknbpa6ev23v7ub